![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/18/2900297/0/en/Vyluma-Meets-with-FDA-on-Atropine-Sulfate-Ophthalmic-Solution-0-01-Under-Development-to-Treat-Pediatric-Myopia.html
https://www.globenewswire.com/news-release/2024/05/29/2889739/0/en/Vyluma-Announces-Marketing-Authorization-Application-Validation-for-the-European-Union.html
https://www.globenewswire.com//news-release/2023/10/11/2758185/0/en/Vyluma-Announces-Positive-Results-From-Second-Stage-of-Phase-III-CHAMP-Study-of-NVK002-for-the-Treatment-of-Myopia-in-Children.html
https://www.globenewswire.com/news-release/2023/06/06/2682640/0/en/Vyluma-Announces-FDA-Acceptance-of-New-Drug-Application-for-NVK002-Its-Novel-Investigational-Treatment-for-Pediatric-Myopia.html
https://www.globenewswire.com//news-release/2023/01/05/2583512/0/en/Vyluma-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2022/10/27/2543149/0/en/Vyluma-Announces-Positive-Results-From-Phase-III-CHAMP-Study-of-NVK002-for-Treatment-of-Myopia-Progression-in-Children.html
https://www.globenewswire.com/news-release/2022/09/01/2508361/0/en/Vyluma-Completes-Last-Patient-Visit-for-Primary-Analysis-of-Pivotal-Phase-III-CHAMP-Study-Evaluating-NVK002-for-the-Treatment-of-Myopia-Progression-in-Children.html